VPC
Vestal Point Capital Portfolio holdings
AUM
$1.9B
1-Year Return
12.28%
This Quarter Return
+0.42%
1 Year Return
-12.28%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.9B
AUM Growth
+$499M
(+36%)
Cap. Flow
+$501M
Cap. Flow
% of AUM
26.36%
Top 10 Holdings %
Top 10 Hldgs %
45.18%
Holding
85
New
22
Increased
26
Reduced
12
Closed
13
Top Buys
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$127M |
| 2 |
Alcon
ALC
|
+$46.3M |
| 3 |
Revolution Medicines
RVMD
|
+$44.1M |
| 4 |
Amicus Therapeutics
FOLD
|
+$43.7M |
| 5 |
Exact Sciences
EXAS
|
+$37.2M |
Top Sells
| 1 |
Insmed
INSM
|
+$82M |
| 2 |
UroGen Pharma
URGN
|
+$23.8M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
+$18.1M |
| 4 |
Liquidia Corp
LQDA
|
+$18.1M |
| 5 |
Establishment Labs
ESTA
|
+$17.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Arcellx
ACLX
$3.94B
| $181M | 9.53% |
2,750,000
+362,280
| +15% | +$23.9M |
|
|
2
Jazz Pharmaceuticals
JAZZ
$7.88B
| $127M | 6.7% |
+1,200,000
| New | +$127M |
|
3
Cytokinetics
CYTK
$6.23B
| $98.3M | 5.18% |
2,975,000
+384,469
| +15% | +$12.7M |
|
4
Nuvalent
NUVL
$5.76B
| $82M | 4.32% |
1,075,000
| – | – |
|
5
Vera Therapeutics
VERA
$1.58B
| $73M | 3.85% |
3,100,000
+600,000
| +24% | +$14.1M |
|
|
6
Amicus Therapeutics
FOLD
$2.46B
| $68.2M | 3.59% |
11,900,000
+7,625,000
| +178% | +$43.7M |
|
7
Xenon Pharmaceuticals
XENE
$2.94B
| $62.6M | 3.3% |
2,000,000
+700,000
| +54% | +$21.9M |
|
8
Dianthus Therapeutics
DNTH
$1.02B
| $59.6M | 3.14% |
3,200,000
+1,499,931
| +88% | +$27.9M |
|
9
Scholar Rock
SRRK
$3.04B
| $53.1M | 2.8% |
1,500,000
+200,000
| +15% | +$7.08M |
|
10
KalVista Pharmaceuticals
KALV
$803M
| $52.9M | 2.78% |
4,675,000
-76,292
| -2% | -$862K |
|
11
GE HealthCare
GEHC
$35.7B
| $51.8M | 2.73% |
700,000
+495,870
| +243% | +$36.7M |
|
12
uniQure
QURE
$956M
| $51.6M | 2.72% |
3,700,000
-1,092,572
| -23% | -$15.2M |
|
|
BCAX
13
Bicara Therapeutics Inc. Common Stock
BCAX
$671M
| $46.5M | 2.45% |
5,000,000
+2,231,025
| +81% | +$20.7M |
|
|
14
Alcon
ALC
$39.5B
| $46.3M | 2.44% |
+525,000
| New | +$46.3M |
|
|
15
Revolution Medicines
RVMD
$7.68B
| $44.1M | 2.32% |
+1,200,000
| New | +$44.1M |
|
16
Crinetics Pharmaceuticals
CRNX
$3.31B
| $43.1M | 2.27% |
1,500,000
| – | – |
|
|
17
Exact Sciences
EXAS
$10.2B
| $37.2M | 1.96% |
+700,000
| New | +$37.2M |
|
18
Celldex Therapeutics
CLDX
$1.55B
| $35.6M | 1.88% |
1,750,000
+1,551,354
| +781% | +$31.6M |
|
19
Ascendis Pharma
ASND
$12.4B
| $34.5M | 1.82% |
200,000
+49,858
| +33% | +$8.61M |
|
20
Immatics
IMTX
$706M
| $33.6M | 1.77% |
6,250,000
-942,700
| -13% | -$5.07M |
|
21
Geron
GERN
$874M
| $33.5M | 1.77% |
23,775,000
+1,769,660
| +8% | +$2.5M |
|
22
Globus Medical
GMED
$8.04B
| $29.5M | 1.55% |
500,000
+300,000
| +150% | +$17.7M |
|
23
BioMarin Pharmaceuticals
BMRN
$10.8B
| $27.5M | 1.45% |
+500,000
| New | +$27.5M |
|
24
MoonLake Immunotherapeutics
MLTX
$3.88B
| $26M | 1.37% |
550,000
+350,000
| +175% | +$16.5M |
|
25
Tyra Biosciences
TYRA
$646M
| $25.4M | 1.34% |
2,655,000
-224,829
| -8% | -$2.15M |
|